Highlights Minerva Neurosciences, Inc.

Equities

NERV

US6033802058

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
2.55 ^USD	+9.91%		+4.44%	-58.54%

May. 01	Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Feb. 27	Sector Update: Health Care Stocks Ease Late Afternoon	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
Minerva Neurosciences Shares Tumble After FDA Rejects Roluperidone for Schizophrenia.	Feb. 27	MT
Minerva Neurosciences Shares Slide on Latest FDA Roluperidone Setback	Feb. 27	DJ
FDA Turns Away Minerva's Roluperidone Schizophrenia Drug	Feb. 27	DJ
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia	Feb. 27	CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-01	CI
Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
North American Morning Briefing : Hopes Build for -3-	23-05-15	DJ
Minerva Neurosciences Says US FDA Accepts Filing of New Drug Application for Roluperidone to Treat Schizophrenia Symptoms	23-05-10	MT
Minerva Neurosciences, Inc. Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia	23-05-01	CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-08	CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-08	CI
Minerva Neurosciences, Inc. Announces Update on its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia	22-12-28	CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
North American Morning Briefing : Midterm Outcome -2-	22-11-09	DJ
North American Morning Briefing : Mood Remains -2-	22-10-18	DJ
Minerva Neurosciences Says FDA Doesn't Accept New Drug Application for Roluperidone; Shares Plunge Pre-Bell	22-10-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Minerva Neurosciences, Inc.

Equities

NERV

US6033802058

Highlights

Filters